<h4>Objective</h4>Next-generation imaging with prostate-specific membrane-antigen Positron Emission Tomography/Computed Tomography (PSMA PET/CT) has emerged as an imaging modality offering high diagnostic accuracy and prognostic biomarkers in the primary staging of prostate cancer (PCa). This evidence concerns the gene FOLH1 and prostate carcinoma.